Evaluation of the new continuous mononuclear cell collection protocol versus an older version on two different apheresis machines

Cell separators are routinely used to collect CD34+ blood stem cells in the context of customized stem cell transplantation procedures. The Spectra Optia (Terumo BCT) is a novel development of the precursor instrument, the Cobe Spectra (Terumo BCT).

[1]  R. Costello,et al.  Peripheral blood stem cells collection on spectra optia apheresis system using the continuous mononuclear cell collection protocol: A single center report of 39 procedures , 2017, Journal of clinical apheresis.

[2]  M. Hundemer,et al.  Comparison between intermittent and continuous spectra optia leukapheresis systems for autologous peripheral blood stem cell collection , 2017, Journal of clinical apheresis.

[3]  E. Scott,et al.  Continuous CD34+ cell collection by a new device is safe and more efficient than by a standard collection procedure: results of a two‐center, crossover, randomized trial , 2016, Transfusion.

[4]  S. Watt,et al.  Human bone marrow processing using a new continuous‐flow cell separation device , 2016, Transfusion.

[5]  K. Douglas,et al.  HPC‐A dose prediction on the optia® cell separator based on a benchmark CE2 collection efficiency: Promoting clinical efficiency, minimizing toxicity, and allowing quality control , 2015, Journal of clinical apheresis.

[6]  G. Tricot,et al.  Evaluation of the spectra Optia® mononuclear cell collection procedure in multiple myeloma patients , 2015, Journal of clinical apheresis.

[7]  E. Scott,et al.  Evaluation of the spectra optia apheresis system for mononuclear cell (MNC) collection in G‐CSF mobilized and nonmobilized healthy donors: Results of a multicenter study , 2014, Journal of clinical apheresis.

[8]  E. Seifried,et al.  Mobilized allogeneic peripheral stem/progenitor cell apheresis with Spectra Optia v.5·0, a novel, automatic interface‐controlled apheresis system: results from the first feasibility trial , 2011, Vox sanguinis.

[9]  H. Einsele,et al.  Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009 , 2010, Bone Marrow Transplantation.

[10]  G. Ehninger,et al.  Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. , 2009, Blood.

[11]  H. Heuft,et al.  Inverse relationship between patient peripheral blood CD34+ cell counts and collection efficiency for CD34+ cellsin two automated leukapheresis systems , 2001, Transfusion.

[12]  J. Mayer,et al.  Bone marrow processing for transplantation using the COBE spectra cell separator. , 1999, Journal of hematotherapy & stem cell research.

[13]  F. Cavalli,et al.  Intrapatient Comparison of an Intermittent and a Continous Flow Cell Separator for the Collection of Progenitor and Stem Cells from the Blood , 1998, Vox Sanguinis.

[14]  N. Schmitz,et al.  Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998 , 1998, Bone Marrow Transplantation.

[15]  N. Schmitz,et al.  G‐CSF‐mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft , 1994, British journal of haematology.

[16]  J. Duguid,et al.  Continuous flow cell separator use for bone marrow processing. , 1991, Transfusion science.

[17]  P. Mintz,et al.  Comparison of plateletpheresis using two cell separators and identical donors , 1989, Transfusion.

[18]  F. Appelbaum,et al.  Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. , 1978, Blood.